IL5 and asthma: This association with asthma in the PPI network is also consistent with benralizumab’s MoA, that is, benralizumab inhibits the binding between interleukin-5 and the alpha subunit of interleukin-5 receptor and thus blocks the interleukin-5-induced eosinophil-mediated inflammatory response [61].